首页 > 最新文献

Revista clinica espanola最新文献

英文 中文
Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine 西班牙阿利坎特卫生部的医务人员在接种加强剂量疫苗前,使用快速血清学测试法检测 SARS-CoV-2 中和抗体的流行率。
Pub Date : 2024-04-01 DOI: 10.1016/j.rceng.2024.02.013
A.C. Montagud , J. Llenas-García , R. Moragues , A. Pérez-Bernabeu , M.J. Alcocer Pertegal , F.J. García Gómez , A.M. Gamayo Serna , H. García Morante , P. Caballero , J. Tuells

Aim

To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech).

Materials and Methods

In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a “point-of-care” immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine.

Results

We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies.

Conclusions

The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers.

目的:研究接种第二剂 BNT162b2 疫苗(辉瑞生物技术公司)后,医护人员和医护辅助人员体内中和抗体的流行情况:2021 年 12 月,我们在西班牙阿利坎特省奥里胡埃拉市卫生局开展了一项研究,该卫生局共有 1500 名工作人员。我们收集了研究参与者的人口统计学变量,并进行了 "床旁 "免疫层析测试,以检测是否存在中和抗体(OJABIO® SARS-CoV-2 中和抗体检测试剂盒,温州欧佳生物科技有限公司生产)。结果:我们获得了 964 名工人(64%)的完整信息,其中男性 290 人,女性 674 人。平均年龄为 45.8 岁(最小 18 岁,最大 68 岁),距上次接种疫苗的平均时间为 40.5 周(最小 1.71 周,最大 47.71 周)。共有 131 名参与者(13.5%)通过 RT-PCR 技术确认感染了 SARS-CoV-2。出现中和抗体的参与者比例为 38.5%。在多变量分析中,距最后一次接种疫苗的时间(aOR 周数:1.07;95%CI:1.04;1.09)和之前感染 SARS-CoV-2 的时间(aOR:3.7;95%CI:2.39;5.63)与中和抗体的存在有显著的统计学关联:结论:38.5% 的医护人员和辅助人员体内是否存在中和抗体取决于注射最后一剂疫苗后的时间和以前是否感染过 SARS-CoV-2。
{"title":"Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine","authors":"A.C. Montagud ,&nbsp;J. Llenas-García ,&nbsp;R. Moragues ,&nbsp;A. Pérez-Bernabeu ,&nbsp;M.J. Alcocer Pertegal ,&nbsp;F.J. García Gómez ,&nbsp;A.M. Gamayo Serna ,&nbsp;H. García Morante ,&nbsp;P. Caballero ,&nbsp;J. Tuells","doi":"10.1016/j.rceng.2024.02.013","DOIUrl":"10.1016/j.rceng.2024.02.013","url":null,"abstract":"<div><h3>Aim</h3><p>To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech).</p></div><div><h3>Materials and Methods</h3><p>In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a “point-of-care” immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine.</p></div><div><h3>Results</h3><p>We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies.</p></div><div><h3>Conclusions</h3><p>The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 197-203"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebral venous thrombosis 脑静脉血栓
Pub Date : 2024-04-01 DOI: 10.1016/j.rceng.2024.02.015
L. Ordieres-Ortega , S. Moragón-Ledesma , P. Demelo-Rodríguez

Cerebral venous thrombosis is part of the so-called thrombosis in unusual sites. It is defined as an occlusion in the cerebral venous territory. Its incidence is progressively increasing, especially in developing countries. It is more frequently observed in young women, with hormonal factors such as pregnancy or hormonal contraception being significant risk factors in the development of this condition. The clinical presentation will depend fundamentally on the topography of the thrombosis, with a confirmatory diagnosis based mainly on imaging tests. The treatment generally consists of anticoagulation, and other options may be considered depending on the severity of the case. Overall, the prognosis is better than that of other intracranial vascular disorders. This review describes the current evidence available regarding cerebral venous thrombosis.

脑静脉血栓是所谓非正常部位血栓的一部分。它被定义为脑静脉区域的闭塞。其发病率正在逐步上升,尤其是在发展中国家。这种疾病多见于年轻女性,妊娠或荷尔蒙避孕等荷尔蒙因素是发病的重要危险因素。临床表现主要取决于血栓形成的地形,确诊主要依靠影像学检查。治疗一般包括抗凝治疗,也可根据病情严重程度考虑其他治疗方案。总体而言,预后优于其他颅内血管疾病。本综述介绍了有关脑静脉血栓形成的现有证据。
{"title":"Cerebral venous thrombosis","authors":"L. Ordieres-Ortega ,&nbsp;S. Moragón-Ledesma ,&nbsp;P. Demelo-Rodríguez","doi":"10.1016/j.rceng.2024.02.015","DOIUrl":"10.1016/j.rceng.2024.02.015","url":null,"abstract":"<div><p>Cerebral venous thrombosis is part of the so-called thrombosis in unusual sites. It is defined as an occlusion in the cerebral venous territory. Its incidence is progressively increasing, especially in developing countries. It is more frequently observed in young women, with hormonal factors such as pregnancy or hormonal contraception being significant risk factors in the development of this condition. The clinical presentation will depend fundamentally on the topography of the thrombosis, with a confirmatory diagnosis based mainly on imaging tests. The treatment generally consists of anticoagulation, and other options may be considered depending on the severity of the case. Overall, the prognosis is better than that of other intracranial vascular disorders. This review describes the current evidence available regarding cerebral venous thrombosis.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 237-244"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological aspects, clinical management and short-term outcomes in elderly patients diagnosed with acute heart failure in the emergency department in Spain: results of the EDEN-34 study 西班牙急诊科诊断为急性心力衰竭的老年患者的流行病学、临床管理和短期疗效:EDEN-34 研究结果。
Pub Date : 2024-04-01 DOI: 10.1016/j.rceng.2024.02.014
Ò. Miró , P. Llorens , S. Aguiló , A. Alquézar-Arbé , C. Fernández , G. Burillo-Putze , N.C. Marcos , A.A. Marañón , G.S. Oms , J.G. del Castillo , SIESTA* (Spanish Investigators in Emergency Situations TeAm)

Objective

To estimate the incidence of acute heart failure (AHF) diagnosis in elderly patients in emergency departments (ED), diagnostic confirmation in hospitalized patients, and short-term adverse events.

Methods

All patients aged ≥65 years attended in 52 Spanish EDs during 1 week were included and those diagnosed with AHF were selected. In hospitalized patients, those diagnosed with AHF at discharge were collected. As adverse events, in-hospital and 30-day mortality, and combined adverse event (death or hospitalization) at 30 days post-discharge were collected. Adjusted odds ratios (OR) for association of demographic variables, baseline status and constants at ED arrival with mortality and 30-day post-discharge adverse event were calculated.

Results

We included 1,155 patients with AHF (annual incidence: 26.5 per 1000 inhabitants ≥65 years, 95% CI: 25.0–28.1). In 86% the diagnosis of AHF was known at discharge. Overall 30-day mortality was 10.7% and in-hospital mortality was 7.9%, and the combined event in 15.6%. In-hospital and 30-day mortality was associated with arterial hypotension (adjusted OR: 74.0, 95% CI: 5.39–1015. and 42.6, 3.74–485, respectively and hypoxemia (2.14, 1.27–3.61; and 1.87, 1.19–2.93) on arrival at the ED and requiring assistance with ambulation (2.24, 1.04–4.83; and 2.48, 1.27–4.86) and age (per 10-year increment; 1.54, 1.04–2.29; and 1.60, 1.13–2.28). The combined post-discharge adverse event was not associated with any characteristic.

Conclusions

AHF is a frequent diagnosis in elderly patients consulting in the ED. The functional impairment, age, hypotension and hypoxemia are the factors most associated with mortality.

目的估计急诊科(ED)老年患者急性心力衰竭(AHF)的诊断率、住院患者的确诊率以及短期不良反应:纳入一周内在西班牙 52 家急诊室就诊的所有年龄≥65 岁的患者,并选择确诊为急性心力衰竭的患者。在住院患者中,收集出院时确诊为 AHF 的患者。作为不良事件,收集了院内和 30 天死亡率以及出院后 30 天的综合不良事件(死亡或住院)。计算了人口统计学变量、基线状态和到达急诊室时的常数与死亡率和出院后 30 天不良事件的调整赔率比(OR):我们纳入了 1,155 名 AHF 患者(年发病率:每 1000 名年龄≥65 岁的居民中 26.5 例,95% CI:25.0-28.1 例)。86%的患者在出院时已确诊为急性肾功能衰竭。30天总死亡率为10.7%,院内死亡率为7.9%,合并死亡率为15.6%。院内和 30 天死亡率与动脉低血压(调整后 OR:74.0,95% CI:5.39-1015.和 42.6,3.74-485.)和低氧血症(2.14,1.27-3.61;1.87,1.19-2.93)、到达急诊室时需要协助行走(2.24,1.04-4.83;和 2.48,1.27-4.86)和年龄(每 10 年递增;1.54,1.04-2.29;和 1.60,1.13-2.28)。综合出院后不良事件与任何特征均无关联:结论:在急诊室就诊的老年患者中,AHF是一种常见诊断。结论:AHF是急诊室就诊的老年患者的常见诊断,功能障碍、年龄、低血压和低氧血症是与死亡率最相关的因素。
{"title":"Epidemiological aspects, clinical management and short-term outcomes in elderly patients diagnosed with acute heart failure in the emergency department in Spain: results of the EDEN-34 study","authors":"Ò. Miró ,&nbsp;P. Llorens ,&nbsp;S. Aguiló ,&nbsp;A. Alquézar-Arbé ,&nbsp;C. Fernández ,&nbsp;G. Burillo-Putze ,&nbsp;N.C. Marcos ,&nbsp;A.A. Marañón ,&nbsp;G.S. Oms ,&nbsp;J.G. del Castillo ,&nbsp;SIESTA* (Spanish Investigators in Emergency Situations TeAm)","doi":"10.1016/j.rceng.2024.02.014","DOIUrl":"10.1016/j.rceng.2024.02.014","url":null,"abstract":"<div><h3>Objective</h3><p>To estimate the incidence of acute heart failure (AHF) diagnosis in elderly patients in emergency departments (ED), diagnostic confirmation in hospitalized patients, and short-term adverse events.</p></div><div><h3>Methods</h3><p>All patients aged ≥65 years attended in 52 Spanish EDs during 1 week were included and those diagnosed with AHF were selected. In hospitalized patients, those diagnosed with AHF at discharge were collected. As adverse events, in-hospital and 30-day mortality, and combined adverse event (death or hospitalization) at 30 days post-discharge were collected. Adjusted odds ratios (OR) for association of demographic variables, baseline status and constants at ED arrival with mortality and 30-day post-discharge adverse event were calculated.</p></div><div><h3>Results</h3><p>We included 1,155 patients with AHF (annual incidence: 26.5 per 1000 inhabitants ≥65 years, 95% CI: 25.0–28.1). In 86% the diagnosis of AHF was known at discharge. Overall 30-day mortality was 10.7% and in-hospital mortality was 7.9%, and the combined event in 15.6%. In-hospital and 30-day mortality was associated with arterial hypotension (adjusted OR: 74.0, 95% CI: 5.39–1015. and 42.6, 3.74–485, respectively and hypoxemia (2.14, 1.27–3.61; and 1.87, 1.19–2.93) on arrival at the ED and requiring assistance with ambulation (2.24, 1.04–4.83; and 2.48, 1.27–4.86) and age (per 10-year increment; 1.54, 1.04–2.29; and 1.60, 1.13–2.28). The combined post-discharge adverse event was not associated with any characteristic.</p></div><div><h3>Conclusions</h3><p>AHF is a frequent diagnosis in elderly patients consulting in the ED. The functional impairment, age, hypotension and hypoxemia are the factors most associated with mortality.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 204-216"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to detect non-institutionalized older patients at risk of malnutrition during their hospitalization? Comparison of 8 screening tools for malnutrition or nutritional risk 如何检测住院期间有营养不良风险的非住院老年患者?比较 8 种营养不良或营养风险筛查工具。
Pub Date : 2024-04-01 DOI: 10.1016/j.rceng.2024.03.003
I. García-Fuente , L. Corral-Gudino , M. Gabella-Martín , V.E. Olivet-de-la-Fuente , J. Pérez-Nieto , P. Miramontes-González

Background

The prevalence of malnutrition is high among the elderly population. Hospital admission is a window of opportunity for its detection.

Objective

To assess the concordance of different nutritional scales in hospitalized patients.

Methods

Prospective study in non-institutionalized patients over 65 years of age admitted to an internal medicine department. Five malnutrition screening surveys (MNA, MST, MUST, NRS-2000 and CONUT) and three nutritional risk screening surveys (SCREEN 3, 8 and 14) were compared. As gold standard we use the Global Malnutrition Leadership Initiative for Malnutrition (GLIM) definition of malnutrition.

Results

Eighty-five patients (37% female, median age 83 years) were included. Forty-eight percent (95% CI 38–59%) of patients were classified as malnourished according to GLIM criteria. The SCREEN 3 scale was the most sensitive (93%; 95% CI 87–98) and MUST the most specific (91%; CI 85–99). The most effective scale for excluding suspected malnutrition was SCREEN 3 (LR− 0.17; 95% CI 0.05−0.53) and the best for confirming it was MST (LR+ 7.08; 95% CI 3.06–16.39). Concordance between the different scales was low or very low with kappa indices between 0.082 and 0.465.

Conclusions

A comprehensive approach is needed to detect malnutrition in hospitalized patients. More sensitive scales are more useful in initial screening. Nutritional risk tools could be effective at this stage. In a second step, malnutrition should be confirmed according to established criteria such as GLIM.

背景:营养不良在老年人口中的发病率很高。入院是发现营养不良的机会之窗:评估住院患者不同营养量表的一致性:方法:对在内科住院的 65 岁以上非住院患者进行前瞻性研究。比较了五种营养不良筛查调查(MNA、MST、MUST、NRS-2000 和 CONUT)和三种营养风险筛查调查(SCREEN 3、8 和 14)。我们采用全球营养不良领导倡议(GLIM)的营养不良定义作为金标准:共纳入 85 名患者(37% 为女性,中位年龄为 83 岁)。根据 GLIM 标准,48%(95% CI 38-59%)的患者被归类为营养不良。SCREEN 3量表的灵敏度最高(93%;95% CI 87-98),MUST的特异度最高(91%;CI 85-99)。排除疑似营养不良的最有效量表是 SCREEN 3(LR- 0.17;95% CI 0.05-0.53),而确认营养不良的最佳量表是 MST(LR + 7.08;95% CI 3.06-16.39)。不同量表之间的一致性较低或很低,卡帕指数介于 0.082 和 0.465 之间:结论:需要采用综合方法来检测住院患者的营养不良状况。结论:需要采用综合方法检测住院病人的营养不良情况,灵敏度较高的量表在初步筛查中更有用。营养风险工具可在此阶段发挥有效作用。第二步,应根据 GLIM 等既定标准确认营养不良。
{"title":"How to detect non-institutionalized older patients at risk of malnutrition during their hospitalization? Comparison of 8 screening tools for malnutrition or nutritional risk","authors":"I. García-Fuente ,&nbsp;L. Corral-Gudino ,&nbsp;M. Gabella-Martín ,&nbsp;V.E. Olivet-de-la-Fuente ,&nbsp;J. Pérez-Nieto ,&nbsp;P. Miramontes-González","doi":"10.1016/j.rceng.2024.03.003","DOIUrl":"10.1016/j.rceng.2024.03.003","url":null,"abstract":"<div><h3>Background</h3><p>The prevalence of malnutrition is high among the elderly population. Hospital admission is a window of opportunity for its detection.</p></div><div><h3>Objective</h3><p>To assess the concordance of different nutritional scales in hospitalized patients.</p></div><div><h3>Methods</h3><p>Prospective study in non-institutionalized patients over 65 years of age admitted to an internal medicine department. Five malnutrition screening surveys (MNA, MST, MUST, NRS-2000 and CONUT) and three nutritional risk screening surveys (SCREEN 3, 8 and 14) were compared. As gold standard we use the Global Malnutrition Leadership Initiative for Malnutrition (GLIM) definition of malnutrition.</p></div><div><h3>Results</h3><p>Eighty-five patients (37% female, median age 83 years) were included. Forty-eight percent (95% CI 38–59%) of patients were classified as malnourished according to GLIM criteria. The SCREEN 3 scale was the most sensitive (93%; 95% CI 87–98) and MUST the most specific (91%; CI 85–99). The most effective scale for excluding suspected malnutrition was SCREEN 3 (LR− 0.17; 95% CI 0.05−0.53) and the best for confirming it was MST (LR+ 7.08; 95% CI 3.06–16.39). Concordance between the different scales was low or very low with kappa indices between 0.082 and 0.465.</p></div><div><h3>Conclusions</h3><p>A comprehensive approach is needed to detect malnutrition in hospitalized patients. More sensitive scales are more useful in initial screening. Nutritional risk tools could be effective at this stage. In a second step, malnutrition should be confirmed according to established criteria such as GLIM.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 4","pages":"Pages 217-224"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure 慢性阻塞性肺病和支气管哮喘对心力衰竭患者预后的影响。
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.01.007
E. Barge-Caballero , J. Sieira-Hermida , G. Barge-Caballero , D. Couto-Mallón , M.J. Paniagua-Martín , D. Enríquez-Vázquez , P.J. Marcos-Rodríguez , J. Rodríguez-Capitán , J.M. Vázquez-Rodríguez , M.G. Crespo-Leiro

Purpose

To analyze the impact of chronic obstructive pulmonary disease (COPD) and bronchial asthma on therapeutic management and prognosis of patients with heart failure (HF).

Methods

Analysis of the information collected in a clinical registry of patients referred to a specialized HF unit from January-2010 to June-2012. Clinical profile, treatment and prognosis of patients was evaluated, according to the presence of COPD or asthma. Survival analyses were conducted by means of Kaplan-Meier and Cox’s methods. Median follow-up was 1493 days.

Results

We studied 2577 patients, of which 251 (9.7%) presented COPD and 96 (3.7%) bronchial asthma. Significant differences among study groups were observed regarding to the prescription of beta-blockers (COPD = 89.6%; asthma = 87.5%; no bronchopathy = 94.1%; p = 0.002) and SGLT2 inhibitors (COPD = 35.1%; asthma = 50%; no bronchopathy = 38.3%; p = 0.036). Also, patients with bronchial disease received less frequently a defibrillator (COPD = 20.3%; asthma = 20.8%; no broncopathy = 29%; p = 0.004).

COPD was independently associated with increased risk of all-cause mortality (HR = 1.64; 95% CI 1.33–2.02), all-cause death or HF admission (HR = 1.47; 95% CI 1.22–1.76) and cardiovascular death or heart transplantation (HR = 1.39; 95% CI 1.08–1.79) as compared with patients with no bronchopathy. Bronchial asthma was not significantly associated with increased risk of adverse outcomes.

Conclusions

COPD, but not asthma, is an adverse independent prognostic factor in patients with HF.

目的:分析慢性阻塞性肺疾病(COPD)和支气管哮喘对心力衰竭(HF)患者治疗管理和预后的影响:分析 2010 年 1 月至 2012 年 6 月期间转诊至心力衰竭专科的患者的临床登记信息。根据是否患有慢性阻塞性肺病或哮喘,对患者的临床概况、治疗和预后进行评估。采用 Kaplan-Meier 和 Cox´s 方法进行生存分析。中位随访时间为 1493 天:我们对 2577 名患者进行了研究,其中 251 人(9.7%)患有慢性阻塞性肺病,96 人(3.7%)患有支气管哮喘。研究组之间在使用β-受体阻滞剂(慢性阻塞性肺病=89.6%;哮喘=87.5%;无支气管病变=94.1%;P=0.002)和 SGLT2 抑制剂(慢性阻塞性肺病=35.1%;哮喘=50%;无支气管病变=38.3%;P=0.036)方面存在显著差异。此外,支气管疾病患者使用除颤器的频率较低(慢性阻塞性肺病=20.3%;哮喘=20.8%;无支气管病变=29%;P=0.004)。与无支气管病变的患者相比,慢性阻塞性肺病与全因死亡(HR = 1.64;95% CI 1.33-2.02)、全因死亡或入住高频病房(HR = 1.47;95% CI 1.22-1.76)和心血管死亡或心脏移植(HR = 1.39;95% CI 1.08-1.79)的风险增加有独立关联。支气管哮喘与不良后果风险的增加无明显关联:结论:慢性阻塞性肺病(而非哮喘)是心房颤动患者的一个独立不良预后因素。
{"title":"Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure","authors":"E. Barge-Caballero ,&nbsp;J. Sieira-Hermida ,&nbsp;G. Barge-Caballero ,&nbsp;D. Couto-Mallón ,&nbsp;M.J. Paniagua-Martín ,&nbsp;D. Enríquez-Vázquez ,&nbsp;P.J. Marcos-Rodríguez ,&nbsp;J. Rodríguez-Capitán ,&nbsp;J.M. Vázquez-Rodríguez ,&nbsp;M.G. Crespo-Leiro","doi":"10.1016/j.rceng.2024.01.007","DOIUrl":"10.1016/j.rceng.2024.01.007","url":null,"abstract":"<div><h3>Purpose</h3><p>To analyze the impact of chronic obstructive pulmonary disease (COPD) and bronchial asthma on therapeutic management and prognosis of patients with heart failure (HF).</p></div><div><h3>Methods</h3><p>Analysis of the information collected in a clinical registry of patients referred to a specialized HF unit from January-2010 to June-2012. Clinical profile, treatment and prognosis of patients was evaluated, according to the presence of COPD or asthma. Survival analyses were conducted by means of Kaplan-Meier and Cox’s methods. Median follow-up was 1493 days.</p></div><div><h3>Results</h3><p>We studied 2577 patients, of which 251 (9.7%) presented COPD and 96 (3.7%) bronchial asthma. Significant differences among study groups were observed regarding to the prescription of beta-blockers (COPD<!--> <!-->=<!--> <!-->89.6%; asthma<!--> <!-->=<!--> <!-->87.5%; no bronchopathy<!--> <!-->=<!--> <!-->94.1%; p<!--> <!-->=<!--> <!-->0.002) and SGLT2 inhibitors (COPD<!--> <!-->=<!--> <!-->35.1%; asthma<!--> <!-->=<!--> <!-->50%; no bronchopathy<!--> <!-->=<!--> <!-->38.3%; <em>p</em> <!-->=<!--> <!-->0.036). Also, patients with bronchial disease received less frequently a defibrillator (COPD<!--> <!-->=<!--> <!-->20.3%; asthma<!--> <!-->=<!--> <!-->20.8%; no broncopathy<!--> <!-->=<!--> <!-->29%; <em>p</em> <!-->=<!--> <!-->0.004).</p><p>COPD was independently associated with increased risk of all-cause mortality (HR<!--> <!-->=<!--> <!-->1.64; 95% CI 1.33–2.02), all-cause death or HF admission (HR<!--> <!-->=<!--> <!-->1.47; 95% CI 1.22–1.76) and cardiovascular death or heart transplantation (HR<!--> <!-->=<!--> <!-->1.39; 95% CI 1.08–1.79) as compared with patients with no bronchopathy. Bronchial asthma was not significantly associated with increased risk of adverse outcomes.</p></div><div><h3>Conclusions</h3><p>COPD, but not asthma, is an adverse independent prognostic factor in patients with HF.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 123-132"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139704404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors 因子 XI 抑制剂抗血栓治疗临床试验的系统回顾。
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.01.006
A. Franco-Moreno , N. Muñoz-Rivas , J. Torres-Macho , A. Bustamante-Fermosel , C.L. Ancos-Aracil , E. Madroñal-Cerezo

Introduction and objective

Data from phase 2 clinical trials suggest that factor XI inhibitors may exhibit a more favorable efficacy/safety profile compared to current antithrombotic therapies. The aim of this systematic review is to analyze the available evidence derived from these studies.

Methods

A literature search in the PubMed, Cochrane Library, Scopus, EMBASE databases, and clinical trial registration platforms Clinical Trials and Cochrane Central Register of Controlled was conducted. In accordance with the PRISMA statement, results were reported.

Results

A total of 18 completed or ongoing clinical trials addressing multiple scenarios, including atrial fibrillation, stroke, myocardial infarction, and venous thromboembolism, were identified. Evidence from 8 studies with available results was analyzed. Phase 2 studies with factor XI inhibitors, overall, demonstrated an acceptable efficacy and safety profile. The benefit-risk balance, in terms of reducing venous thromboembolism in patients undergoing total knee arthroplasty, was more favorable. For this scenario, factor XI inhibitors showed a 50% reduction in the overall rate of thrombotic complications and a 60% reduction in the rate of bleeding compared to enoxaparin. Modest results in studies involving patients with atrial fibrillation, stroke, and myocardial infarction were observed.

Conclusions

Factor XI inhibitors offer new prospects in antithrombotic treatment and prophylaxis. Ongoing phase 3 studies will help define the most suitable drugs and indications.

简介和目的:二期临床试验数据表明,与目前的抗血栓疗法相比,因子 XI 抑制剂可能具有更佳的疗效/安全性。本系统综述旨在分析从这些研究中获得的现有证据:方法:在 PubMed、Cochrane Library、Scopus、EMBASE 数据库以及临床试验注册平台 Clinical Trials 和 Cochrane Central Register of Controlled 中进行文献检索。根据 PRISMA 声明报告结果:结果:共确定了 18 项已完成或正在进行的临床试验,涉及多种情况,包括心房颤动、中风、心肌梗死和静脉血栓栓塞。对 8 项已有结果的研究中的证据进行了分析。总体而言,因子 XI 抑制剂的 2 期研究显示了可接受的疗效和安全性。就减少全膝关节置换术患者静脉血栓栓塞而言,其效益与风险的平衡更为有利。在这种情况下,与依诺肝素相比,因子 XI 抑制剂的血栓并发症总发生率降低了 50%,出血率降低了 60%。在涉及心房颤动、中风和心肌梗死患者的研究中,观察到的结果并不明显:因子 XI 抑制剂为抗血栓治疗和预防提供了新的前景。正在进行的 3 期研究将有助于确定最合适的药物和适应症。
{"title":"Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors","authors":"A. Franco-Moreno ,&nbsp;N. Muñoz-Rivas ,&nbsp;J. Torres-Macho ,&nbsp;A. Bustamante-Fermosel ,&nbsp;C.L. Ancos-Aracil ,&nbsp;E. Madroñal-Cerezo","doi":"10.1016/j.rceng.2024.01.006","DOIUrl":"10.1016/j.rceng.2024.01.006","url":null,"abstract":"<div><h3>Introduction and objective</h3><p>Data from phase 2 clinical trials suggest that factor XI inhibitors may exhibit a more favorable efficacy/safety profile compared to current antithrombotic therapies. The aim of this systematic review is to analyze the available evidence derived from these studies.</p></div><div><h3>Methods</h3><p>A literature search in the PubMed, Cochrane Library, Scopus, EMBASE databases, and clinical trial registration platforms Clinical Trials and Cochrane Central Register of Controlled was conducted. In accordance with the PRISMA statement, results were reported.</p></div><div><h3>Results</h3><p>A total of 18 completed or ongoing clinical trials addressing multiple scenarios, including atrial fibrillation, stroke, myocardial infarction, and venous thromboembolism, were identified. Evidence from 8 studies with available results was analyzed. Phase 2 studies with factor XI inhibitors, overall, demonstrated an acceptable efficacy and safety profile. The benefit-risk balance, in terms of reducing venous thromboembolism in patients undergoing total knee arthroplasty, was more favorable. For this scenario, factor XI inhibitors showed a 50% reduction in the overall rate of thrombotic complications and a 60% reduction in the rate of bleeding compared to enoxaparin. Modest results in studies involving patients with atrial fibrillation, stroke, and myocardial infarction were observed.</p></div><div><h3>Conclusions</h3><p>Factor XI inhibitors offer new prospects in antithrombotic treatment and prophylaxis. Ongoing phase 3 studies will help define the most suitable drugs and indications.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 167-177"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139682297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semi-quantitative pulmonary congestion score: prevalence and diuretic management implications after heart failure discharge 半定量肺充血评分:心力衰竭出院后的发病率和利尿剂管理影响。
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.02.002
F.J. Pastor-Pérez, M. Veas-Porlán, N. Fernández-Villa, I.P. Garrido-Bravo, S. Manzano-Fernández, D.A. Pascual-Figal

Introduction

Persistent congestion after heart failure (HF) discharge is associated with a higher risk of readmissions.

Material and methods

eighty-two patients included after HF discharge. The aim of the study was to characterize semiquantitatively the degree of pulmonary congestion and its changes, describing the relationship between these findings and diuretic management.

Results

On the first visit, despite the absence of clinical congestion in the majority of patients, half of the had some degree of pulmonary congestion by ultrasound. After global assessment in this initial visit (clinical and ultrasound) the diuretic was lowered in 50 patients (60%), kept the same in 16 (20%) and it was increased in the rest. In the 45 patients without ultrasound congestion, diuretic reduction was attempted in 80%, being this strategy successful in the majority of them.

Conclusions

Lung ultrasound, using simple quantification methods, allows its real incorporation into clinical practice, helping us in the decision making process.

导言心力衰竭(HF)出院后持续充血与再入院的风险较高有关。研究目的是对肺充血程度及其变化进行半定量分析,描述这些结果与利尿剂管理之间的关系:在首次就诊时,尽管大多数患者没有临床充血症状,但半数患者经超声检查有一定程度的肺充血。在首次就诊时进行全面评估(临床和超声)后,50 名患者(60%)的利尿剂用量减少,16 名患者(20%)的利尿剂用量保持不变,其余患者的利尿剂用量增加。在 45 名未出现超声波充血的患者中,80% 的患者尝试减少了利尿剂用量,其中大部分患者的策略都取得了成功:结论:肺部超声波采用简单的量化方法,可以真正应用于临床实践,帮助我们做出决策。
{"title":"Semi-quantitative pulmonary congestion score: prevalence and diuretic management implications after heart failure discharge","authors":"F.J. Pastor-Pérez,&nbsp;M. Veas-Porlán,&nbsp;N. Fernández-Villa,&nbsp;I.P. Garrido-Bravo,&nbsp;S. Manzano-Fernández,&nbsp;D.A. Pascual-Figal","doi":"10.1016/j.rceng.2024.02.002","DOIUrl":"10.1016/j.rceng.2024.02.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Persistent congestion after heart failure (HF) discharge is associated with a higher risk of readmissions.</p></div><div><h3>Material and methods</h3><p>eighty-two patients included after HF discharge. The aim of the study was to characterize semiquantitatively the degree of pulmonary congestion and its changes, describing the relationship between these findings and diuretic management.</p></div><div><h3>Results</h3><p>On the first visit, despite the absence of clinical congestion in the majority of patients, half of the had some degree of pulmonary congestion by ultrasound. After global assessment in this initial visit (clinical and ultrasound) the diuretic was lowered in 50 patients (60%), kept the same in 16 (20%) and it was increased in the rest. In the 45 patients without ultrasound congestion, diuretic reduction was attempted in 80%, being this strategy successful in the majority of them.</p></div><div><h3>Conclusions</h3><p>Lung ultrasound, using simple quantification methods, allows its real incorporation into clinical practice, helping us in the decision making process.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 157-161"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bibliometric analysis of the official journals of internal medicine societies in Europe 欧洲内科医学会官方期刊的文献计量分析。
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.02.004
L. Liesa, J.M. Porcel

Introduction

Bibliometrics evaluates the quality of biomedical journals. The aim of this study has been to compare the main bibliometric indexes of the official journals of scientific societies of Internal Medicine in Europe.

Material and methods

Bibliometric information was obtained from the Web of Science (WoS) and Scopus databases. Both impact metrics (Journal Impact Factor [JIF], CiteScore) and normalized metrics (Journal Citation Indicator [JCI], Normalized Eigenfactor, Source Normalized Impact per Paper [SNIP] and SCImago Journal Rank [SJR]) of the journals for the year 2022 were analyzed, and their evolution over the last decade was described.

Results

Twenty-three official journals from 33 scientific societies were evaluated. Eight journals were included in WoS and 11 in Scopus. The best positioned journals in 2022 were: 1) European Journal of Internal Medicine, which ranked in the first quartile (Q1) for JIF, CiteScore and JCI metrics, exceeding values of 1 in Normalized Eigenfactor and SNIP metrics; 2) Internal and Emergency Medicine, with Q1 for CiteScore and JCI metrics, and with values >1 in Normalized EigenFactor and SNIP metrics; 3) Polish Archives of Internal Medicine, with Q1 for JCI metrics; 4) Revista Clínica Española, with Q2 for JIF, CiteScore and JCI metrics; and 5) Acta Medica Belgica, with Q2 for CiteScore and JCI metrics. These journals increased their impact metrics in the last 3 years, in parallel with the COVID pandemic.

Conclusions

Five official journals of European Internal Medicine societies, including Revista Clínica Española, meet high quality standards.

简介文献计量学评估生物医学期刊的质量。本研究旨在比较欧洲内科学会官方期刊的主要文献计量指数:文献计量学信息来自 Web of Science (WoS) 和 Scopus 数据库。分析了2022年期刊的影响指标(期刊影响因子[JIF]、CiteScore)和归一化指标(期刊引文指标[JCI]、归一化特征因子、每篇论文来源归一化影响[SNIP]和SCImago期刊排名[SJR]),并描述了它们在过去十年中的变化:对 33 个科学协会的 23 种官方期刊进行了评估。8种期刊被WoS收录,11种被Scopus收录。2022 年定位最佳的期刊是1)《欧洲内科学杂志》(European Journal of Internal Medicine),在JIF、CiteScore和JCI指标中排名第一四分位(Q1),归一化特征因子和SNIP指标值超过1;2)《内科和急诊医学》(Internal and Emergency Medicine),在CiteScore和JCI指标中排名第一,归一化特征因子和SNIP指标值大于1;3) 《波兰内科学档案》,JCI 指标为第一季度;4) 《西班牙临床杂志》,JIF、CiteScore 和 JCI 指标为第二季度;5) 《比利时医学杂志》,CiteScore 和 JCI 指标为第二季度。这些期刊的影响指标在过去 3 年中与 COVID 大流行同步增长:结论:包括《Revista Clínica Española》在内的五份欧洲内科学会官方期刊符合高质量标准。
{"title":"Bibliometric analysis of the official journals of internal medicine societies in Europe","authors":"L. Liesa,&nbsp;J.M. Porcel","doi":"10.1016/j.rceng.2024.02.004","DOIUrl":"10.1016/j.rceng.2024.02.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Bibliometrics evaluates the quality of biomedical journals. The aim of this study has been to compare the main bibliometric indexes of the official journals of scientific societies of Internal Medicine in Europe.</p></div><div><h3>Material and methods</h3><p>Bibliometric information was obtained from the Web of Science (WoS) and Scopus databases. Both impact metrics (Journal Impact Factor [JIF], CiteScore) and normalized metrics (Journal Citation Indicator [JCI], Normalized Eigenfactor, Source Normalized Impact per Paper [SNIP] and SCImago Journal Rank [SJR]) of the journals for the year 2022 were analyzed, and their evolution over the last decade was described.</p></div><div><h3>Results</h3><p>Twenty-three official journals from 33 scientific societies were evaluated. Eight journals were included in WoS and 11 in Scopus. The best positioned journals in 2022 were: 1) European Journal of Internal Medicine, which ranked in the first quartile (Q1) for JIF, CiteScore and JCI metrics, exceeding values of 1 in Normalized Eigenfactor and SNIP metrics; 2) Internal and Emergency Medicine, with Q1 for CiteScore and JCI metrics, and with values &gt;1 in Normalized EigenFactor and SNIP metrics; 3) Polish Archives of Internal Medicine, with Q1 for JCI metrics; 4) <span>Revista Clínica Española</span>, with Q2 for JIF, CiteScore and JCI metrics; and 5) Acta Medica Belgica, with Q2 for CiteScore and JCI metrics. These journals increased their impact metrics in the last 3 years, in parallel with the COVID pandemic.</p></div><div><h3>Conclusions</h3><p>Five official journals of European Internal Medicine societies, including <span>Revista Clínica Española</span>, meet high quality standards.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 133-140"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139748041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual dysfunction in women with chronic obstructive lung disease 慢性阻塞性肺病女性患者的性功能障碍。
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.02.007
N. Alcalá-Rivera , J. Díez-Manglano

Objective

To determine the prevalence of sexual dysfunction in women with COPD and the factors related to its presence.

Methods

Cross-sectional observational study during 2021, including women with COPD diagnosed by spirometry through convenience sampling. Data on age, smoking status, spirometric data, comorbidities and medications used were collected. A sexual health questionnaire was administered.

Results

The study included 101 women with a mean age of 59.7 (11.3) years. All had experienced a change in sexual activity, with 44% attributing it to COPD. Among them, 51.5% experienced dyspnea during coitus. The prevalence of sexual dysfunction was 52.5%. Women with sexual dysfunction were older and had a lower Tiffeneau index. Furthermore, they consumed alcohol more frequently and had hypertension and cerebrovascular disease, and less often, they had diabetes and heart failure. However, they scored lower on the Charlson index corrected for age. Patients with sexual dysfunction used inhaled triple therapy less frequently.

Conclusions

Sexual dysfunction is common in women with COPD. Further studies are needed to investigate its causes, mechanisms, and potential treatments.

目的确定慢性阻塞性肺病女性患者中性功能障碍的发生率及其相关因素:方法:2021 年进行的横断面观察研究,通过方便抽样,纳入了通过肺活量测定确诊患有慢性阻塞性肺病的女性患者。收集了有关年龄、吸烟状况、肺活量数据、合并症和所用药物的数据。此外,还进行了性健康问卷调查:研究包括 101 名妇女,平均年龄为 59.7(11.3)岁。所有人都曾经历过性活动的改变,其中 44% 的人将其归咎于慢性阻塞性肺病。其中,51.5%的人在同房时出现呼吸困难。性功能障碍的发生率为 52.5%。有性功能障碍的妇女年龄较大,蒂费诺指数较低。此外,她们饮酒更频繁,患有高血压和脑血管疾病,而患有糖尿病和心力衰竭的则较少。不过,他们在按年龄校正后的夏尔森指数上得分较低。性功能障碍患者使用吸入式三联疗法的频率较低:结论:性功能障碍在女性慢性阻塞性肺病患者中很常见。结论:性功能障碍在慢性阻塞性肺病女性患者中很常见,需要进一步研究其原因、机制和潜在的治疗方法。
{"title":"Sexual dysfunction in women with chronic obstructive lung disease","authors":"N. Alcalá-Rivera ,&nbsp;J. Díez-Manglano","doi":"10.1016/j.rceng.2024.02.007","DOIUrl":"10.1016/j.rceng.2024.02.007","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the prevalence of sexual dysfunction in women with COPD and the factors related to its presence.</p></div><div><h3>Methods</h3><p>Cross-sectional observational study during 2021, including women with COPD diagnosed by spirometry through convenience sampling. Data on age, smoking status, spirometric data, comorbidities and medications used were collected. A sexual health questionnaire was administered.</p></div><div><h3>Results</h3><p>The study included 101 women with a mean age of 59.7 (11.3) years. All had experienced a change in sexual activity, with 44% attributing it to COPD. Among them, 51.5% experienced dyspnea during coitus. The prevalence of sexual dysfunction was 52.5%. Women with sexual dysfunction were older and had a lower Tiffeneau index. Furthermore, they consumed alcohol more frequently and had hypertension and cerebrovascular disease, and less often, they had diabetes and heart failure. However, they scored lower on the Charlson index corrected for age. Patients with sexual dysfunction used inhaled triple therapy less frequently.</p></div><div><h3>Conclusions</h3><p>Sexual dysfunction is common in women with COPD. Further studies are needed to investigate its causes, mechanisms, and potential treatments.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 150-156"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation 西班牙-葡萄牙内科在应对气候变化和环境退化方面的建议
Pub Date : 2024-03-01 DOI: 10.1016/j.rceng.2024.02.005
L. Campos , M.M. Chimeno-Viñas , J. Carretero-Gómez , L. Santos , A. Cabrera-Rayo , P.R. Valdez , R. Gómez-Huelgas , en nombre de las sociedades, colegios, y asociaciones de Medicina Interna de los países de habla hispana y lusa

Facing the severity of the impact of climate change and environmental degradation on human health, 32 Internal Medicine societies, colleges, and associations of 29 Spanish and Portuguese-speaking countries issue a consensus document in which they call for the implication of doctors and all health professionals in the global fight against the causes of these changes. This commitment requires the cooperation of health-related organizations, elaboration and implementation of good environmental sustainability practices, greater awareness of professionals and population, promotion of education and research in this area, increasing climate resilience and environmental sustainability of health systems, combating inequalities and protecting the most vulnerable populations, adopting behaviors that protect the environment, and claiming Internal Medicine as a core specialty for empowerment of the health system to respond to these challenges.

面对气候变化和环境退化对人类健康的严重影响,29 个西语和葡萄牙语国家的 32 个内科医学会、学院和协会发布了一份共识文件,呼吁医生和所有卫生专业人员参与全球抗击这些变化根源的斗争。这一承诺要求卫生相关组织开展合作,制定和实施良好的环境可持续性做法,提高专业人员和民众的认识,促进该领域的教育和研究,增强卫生系统的气候适应能力和环境可持续性,消除不平等现象,保护最弱势人群,采取保护环境的行为,并将内科学作为增强卫生系统应对这些挑战能力的核心专业。
{"title":"Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation","authors":"L. Campos ,&nbsp;M.M. Chimeno-Viñas ,&nbsp;J. Carretero-Gómez ,&nbsp;L. Santos ,&nbsp;A. Cabrera-Rayo ,&nbsp;P.R. Valdez ,&nbsp;R. Gómez-Huelgas ,&nbsp;en nombre de las sociedades, colegios, y asociaciones de Medicina Interna de los países de habla hispana y lusa","doi":"10.1016/j.rceng.2024.02.005","DOIUrl":"https://doi.org/10.1016/j.rceng.2024.02.005","url":null,"abstract":"<div><p>Facing the severity of the impact of climate change and environmental degradation on human health, 32 Internal Medicine societies, colleges, and associations of 29 Spanish and Portuguese-speaking countries issue a consensus document in which they call for the implication of doctors and all health professionals in the global fight against the causes of these changes. This commitment requires the cooperation of health-related organizations, elaboration and implementation of good environmental sustainability practices, greater awareness of professionals and population, promotion of education and research in this area, increasing climate resilience and environmental sustainability of health systems, combating inequalities and protecting the most vulnerable populations, adopting behaviors that protect the environment, and claiming Internal Medicine as a core specialty for empowerment of the health system to respond to these challenges.</p></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"224 3","pages":"Pages 162-166"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2254887424000237/pdfft?md5=e62431d70f249516f790b4e5cd59afd2&pid=1-s2.0-S2254887424000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140062971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista clinica espanola
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1